TRIO Announces Participation in the Avoca Diligent(TM) Prequalification Platform
Diligent Leverages Avoca Quality Consortium(TM) Standards to Improve Quality and Reduce Cycle Time in the Prequalification of Technical Providers
EDMONTON, Alberta, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO) is pleased to announce its participation in the Avoca Diligent(TM) Prequalification Platform. The purpose of this initiative is to increase quality, improve efficiency, reduce risk, and accelerate technical service provider onboarding by centralizing aspects of prequalification activities.
Diligent was created by engaging an expert advisory board from the Avoca Quality Consortium to develop industry standards for prequalification of technical service providers. These standards were mapped, when possible, to health authority regulations or regulatory guidance. They underwent a rigorous review by The Avoca Group, the advisory board, and companies in the industry that deliver these technical services. Upon finalizing the prequalification industry standards, prequalification tools were developed that map back to these standards, including Request for Information (RFI) templates.
The Avoca Group has been inviting leading clinical service providers to submit completed RFIs and centralize them so they are readily available to sponsors (and clinical research organizations (CROs), if applicable) to expedite the process of prequalifying and onboarding new clinical service providers. TRIO has joined this transformational initiative and invites sponsors to contact The Avoca Group at Diligent@theavocagroup.com to request their completed RFI as needed to accelerate their review and onboarding of TRIO for their clinical trials.
"TRIO is excited to take part in the Diligent(TM) Prequalification Platform," shared Dr. Launa Aspeslet, TRIO's Chief Executive Officer. "TRIO is dedicated to bringing forward treatments which will benefit patients with cancer. TRIO is constantly looking at solutions to expedite trial conduct with the utmost quality. We expect this initiative to facilitate collaborations to run cancer clinical trials."
"The Avoca Group is pleased that TRIO has decided to participate in Diligent," says Patricia Leuchten, CEO of The Avoca Group. "This is another example of TRIO's commitment to advancing translational cancer research with novel and innovative approaches to delivering clinical trials efficiently and on time."
TRIO, together with its global network of dedicated investigators, is a not-for-profit academic oncology research organization offering full Clinical Research Organization (CRO) services to conduct its clinical trials. We are dedicated to advancing translational cancer research by bringing innovative and targeted therapeutics to clinical practice. Our mission is to further cancer research through our translational research model led by Dr. Dennis Slamon. TRIO conducts novel clinical trials with designs scientifically based on the preclinical findings from the Translational Oncology Research Laboratory (TORL) at UCLA. Additional information can be found by visiting www.trioncology.org.
About The Avoca Group
The Avoca Group, whose clients include top five pharmaceutical companies and global contract research organizations (CROs), is a driving force behind the continuous improvement of outsourced clinical research. In 2011, the Avoca Quality Consortium(TM), a pre-competitive collaborative, was formed and sponsored by Pfizer and Lilly. Members include more than 70 pharma, biotech, and clinical service providers. Founded in 1999, the company works exclusively in the health care industry with a focus on clinical research and clinical outsourcing. Learn more about The Avoca Group at www.theavocagroup.com and on LinkedIn and Twitter.
Launa Aspeslet, PhD, RAC
Matthieu Rupin, MSc
Business Development Director, TRIO
Email: email@example.com Phone: (+33) 1 58 10 08 89
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Translational Research in Oncology via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Skybox Security Expands Footprint in APAC with New Channel Partners and Leadership in Australia20.6.2018 00:00 | Pressmeddelande
SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, today announced that two Australia-based firms, NEXTGEN and Insentra have joined its Australia channel partner program. In addition, Skybox has filled a key leadership role in Australia and New Zealand, continuing the company's expansion in the Asia Pacific region (APAC), which is among the company's fastest-growing global markets. The Skybox APAC channel program enables managed security service providers (MSSPs), value-added resellers (VARs), distributors and system integrators to meet the needs of the market by deploying and offering services that leverage the Skybox(TM) Security Suite. By adding the Suite to their offerings, local partners can continue to serve as trusted cybersecurity advisors to Australian businesses. "Skybox is working with many of the world's largest, most complex networks, providing security teams with the visibility and context needed to addres
Platinum Equity to Sell Worldwide Flight Services for €1.2 Billion19.6.2018 15:00 | Pressmeddelande
Successful investment adds to Platinum Equity's continued momentum in Europe LOS ANGELES, June 19, 2018 (GLOBE NEWSWIRE) -- Platinum Equity today announced it has signed a definitive agreement to sell Worldwide Flight Services (WFS) to affiliates of Cerberus Capital Management, L.P. in a transaction valued at approximately €1.2 billion. The sale is expected to close during Q4 2018, subject to regulatory approval and certain closing conditions. Since Platinum Equity acquired the company in 2015, WFS has grown significantly, both organically and through a transformative add-on acquisition, and is now the world's largest air cargo handler and one of the world's leading providers of ground handling and technical services, with annual revenues of more than €1.2 billion. "Through a combination of growth and operational initiatives, WFS has evolved and expanded significantly over the past three years and today enjoys record top-line and earnings performance," said Platinum Equity Partner Loui
Quantenna's New QSR10GU-AX Plus Raises the Bar for Wi-Fi Performance and Functionality19.6.2018 14:00 | Pressmeddelande
SAN JOSE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ:QTNA), the innovator and global leader of high performance Wi-Fi solutions, today announced that the QSR10GU-AX Plus, a new enhanced solution targeting gateways and access points based on the draft IEEE 802.11ax standard, is now sampling to select customers. Building upon Quantenna's pioneering QSR10G-AX Wi-Fi platform, QSR10GU-AX Plus offers unique capabilities, including Adaptive 5 GHz, SuperTx and ESP, providing significant performance gains across a variety of home configurations. The QSR10GU-AX Plus can operate concurrently in both 8x8 MIMO in the 5 GHz band and 4x4 MIMO in the 2.4 GHz band supporting a total of 12 streams. Unique features of QSR10GU-AX Plus include: Dynamic switching between 8x8 MIMO and dual 4x4 MIMO in the 5 GHz band by applying adaptive algorithms, enabled by Quantenna's unique baseband and RF architecture design. This provides the end users with the best possible MIMO c
CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents19.6.2018 14:00 | Pressmeddelande
SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline. "Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, P
Glatfelter to Acquire Georgia-Pacific's European Nonwovens Business for $185 Million19.6.2018 13:44 | Pressmeddelande
YORK, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- June 19, 2018 - Glatfelter (NYSE:GLT), a global supplier of specialty papers and engineered materials, today announced it has signed a definitive agreement to purchase Georgia-Pacific's European nonwovens business (the "Business") for $185 million, subject to customary purchase price adjustments. The proposed transaction includes Georgia-Pacific's operations located in Steinfurt, Germany, along with sales offices located in France and Italy. The Steinfurt facility produces high-quality airlaid products for the table-top, wipes, hygiene, food pad, and other nonwoven materials markets, competing in the marketplace with nonwoven technologies and substrates, as well as other materials focused primarily on consumer based end-use applications. The Steinfurt facility is a state-of-the-art, 32,000-metric-ton-capacity manufacturing facility that employs approximately 220 people. "Glatfelter's agreement to acquire the European nonwovens business demon
Industry stakeholders partner on blockchain based margin and collateral solution19.6.2018 13:00 | Pressmeddelande
AMSTERDAM, the Netherlands, BRUSSELS, Belgium, LONDON and STOCKHOLM, Sweden, June 19, 2018 (GLOBE NEWSWIRE) -- ABN AMRO Clearing, EuroCCP, Euroclear and Nasdaq have completed a joint proof of concept to make the use of securities more efficient when used to cover margin calls, including after business hours, using blockchain, or distributed ledger technology (DLT). This solution addresses significant business challenges and inefficiencies related to the current provision of collateral to Central Counterparties (CCPs) and has demonstrated that a shared, resilient network can be built between collateral givers, collateral takers and intermediaries. The inefficiencies of collateral processing have been heightened as a result of recent market changes such as extended trading hours by stock exchanges and the requirement to centrally clear derivatives traded bilaterally (OTC) under the European Market Infrastructure Regulation (EMIR). Today, a CCP margin call typically needs to be covered by
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum